Literature DB >> 9427604

Immunization for Ebola virus infection.

L Xu1, A Sanchez, Z Yang, S R Zaki, E G Nabel, S T Nichol, G J Nabel.   

Abstract

Infection by Ebola virus causes rapidly progressive, often fatal, symptoms of fever, hemorrhage and hypotension. Previous attempts to elicit protective immunity for this disease have not met with success. We report here that protection against the lethal effects of Ebola virus can be achieved in an animal model by immunizing with plasmids encoding viral proteins. We analyzed immune responses to the viral nucleoprotein (NP) and the secreted or transmembrane forms of the glycoprotein (sGP or GP) and their ability to protect against infection in a guinea pig infection model analogous to the human disease. Protection was achieved and correlated with antibody titer and antigen-specific T-cell responses to sGP or GP. Immunity to Ebola virus can therefore be developed through genetic vaccination and may facilitate efforts to limit the spread of this disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9427604     DOI: 10.1038/nm0198-037

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  60 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.

Authors:  J A Wilson; M K Hart
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

5.  Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice.

Authors:  Wenfang Li; Ling Ye; Ricardo Carrion; Gopi S Mohan; Jerritt Nunneley; Hilary Staples; Anysha Ticer; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  J Infect Dis       Date:  2015-04-14       Impact factor: 5.226

6.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 7.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

8.  Bacillus anthracis sortase A (SrtA) anchors LPXTG motif-containing surface proteins to the cell wall envelope.

Authors:  Andrew H Gaspar; Luciano A Marraffini; Elizabeth M Glass; Kristin L Debord; Hung Ton-That; Olaf Schneewind
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

Review 9.  Ebola virus pathogenesis: implications for vaccines and therapies.

Authors:  Nancy Sullivan; Zhi-Yong Yang; Gary J Nabel
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 10.  Role of plasmonics in detection of deadliest viruses: a review.

Authors:  Foozieh Sohrabi; Sajede Saeidifard; Masih Ghasemi; Tannaz Asadishad; Seyedeh Mehri Hamidi; Seyed Masoud Hosseini
Journal:  Eur Phys J Plus       Date:  2021-06-20       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.